Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 6/20 | 0.52 |
| ▸ | KLK7 | P49862 | 6/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 5/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.40 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL759185 | 1.00 | CETP (0.52) | CETPKLK7KLK5NR1H2NR1H3 | |
| SCHEMBL14311138 | 0.90 | CETP (0.46) | CETPKLK7KLK5NR1H2NR1H3 | |
| SCHEMBL13609033 | 0.90 | CETP (0.46) | CETPKLK7KLK5NR1H2NR1H3 | |
| SCHEMBL3950707 | 0.88 | CETP (0.44) | CETPKLK7 | |
| SCHEMBL3942600 | 0.85 | CETP (0.58) | CETPKLK7KLK5NR1H2NR1H3 | |
| SCHEMBL13609119 | 0.85 | CETP (0.58) | CETPKLK7KLK5NR1H2NR1H3 | |
| SCHEMBL4071602 | 0.85 | CETP (0.44) | CETPNR1H2ABCB1 | |
| SCHEMBL14319923 | 0.85 | CETP (0.44) | CETPNR1H2ABCB1 | |
| SCHEMBL759059 | 0.85 | CETP (0.44) | CETPNR1H2ABCB1 | |
| SCHEMBL759308 | 0.85 | CETP (0.44) | CETPNR1H2ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440682-B2 | 4-benzylamino-1-carboxylacyl-piperidine derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2013-05-14 | — | — | US | disclosed |
| US-8440682-B2 | 4-benzylamino-1-carboxylacyl-piperidine derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2013-05-14 | — | — | US | disclosed |
| US-8420641-B2 | Method of inhibiting CETP activity with 4-benzylamino-1-carboxylacyl-piperidine derivatives | NOVARTIS AG (CH) | 2013-04-16 | — | — | US | disclosed |
| US-8420641-B2 | Method of inhibiting CETP activity with 4-benzylamino-1-carboxylacyl-piperidine derivatives | NOVARTIS AG (CH) | 2013-04-16 | — | — | US | disclosed |
| US-20120264773-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | disclosed |
| US-20120264773-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | disclosed |
| US-20120208816-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120208816-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-8193349-B2 | 4-benzylamino-1-carboxylacyl-piperidine derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-8193349-B2 | 4-benzylamino-1-carboxylacyl-piperidine derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-20090118287-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-05-07 | — | — | US | disclosed |
| US-20090118287-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264773-A1 | ORGANIC COMPOUNDS | CETP, NPC1, CES1 | CETP 1/4885KLK7 2016/4885KLK5 2035/4885 |
| US-20090118287-A1 | ORGANIC COMPOUNDS | CETP, NPC1, CES1 | CETP 1/4885KLK7 2016/4885KLK5 2035/4885 |
| US-20120208816-A1 | ORGANIC COMPOUNDS | CETP, NPC1, CES1 | CETP 1/4885KLK7 2016/4885KLK5 2035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.